Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Research Models: PS1 Mutations
PS1 ΔEXON9

General Information

Transgene:     PS1 cDNA, (VRSQ-)

Mutation:       Δ9, wt

Targeted region (if applicable):     n/a

Promoter:         Rat PDGF b-chain (1.4 kb Xba fragment),

Coding region:     1.4 kb PS1 coding region from ATG start to TGA stop site

Intron:         3 kb PS1 intron 5 inserted at endogenous locus in cDNA Poly A tail from SV40

Mouse strain:     Swiss webster (taconic) x B6D2F1 (taconic)

Phenotype

Null mutant phenotype:     n/a

Lethality/viability/fecundity:     normal for all parameters. Above average fecundity.

Homozygous/heterozygous viability:     both are viable

Relative Protein expression level to endogenous:
Beta Amyloid:     n/a
Presenilin:     2-3 folds (by quantitative western)
Tau:     n/a

Neuropathological Analysis:

Histological:     no abnormal pathology up to 2.5 yrs of age

Immunchemical:     no abnormal pathology up to 2.5 yrs of age

Structural:     none

Behavioral:

Morris Water Maze: Abnormal behavior not seen

Other: no behavioral abnormalities seen (spontaneous alternation test and others, see refs 4, 7)

Electrophysiological assessment: altered AHP in mutants (see ref 3)

Other: elevated Ab42 (ref 1), altered mitocondrial activity (see ref 2), disregulation of calcium homeostasis (see refs 2 and 3)

Crosses to create multigenic mouse:     crosses to APPTg2576 to create the PS/APP line, see refs 4-9

Availability

Licensing/academic distribution contact information:

Wendy Davies,
University of South Florida  
WDAVIS@RESEARCH.USF.EDU

Patents:   

Patent No.
Title
Assignee/Inventors
Filing Date
Issue Date
5,898,094 Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes University of South Florida/Duff; Karen; Hardy; John 7/30/97 4/27/99

Reference

Primary:

1. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M.N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J. and Younkin, S. (1996) Increased amyloid-Beta 42(43) in brains of mice expressing mutant presenilin 1. Nature 383 710-713. Abstract.

2. Bengley J, Duan W, Chan S, Duff K and Mattson M. (1999) Altered calcium homeostasis and mitocondrial dysfunction in cortical synaptic compartments of PS1 mutant mice. J. Neurochem, 72 (3) 1030-1039. Abstract.

3. Barrow PA, Empson RM, Gladwell SJ, Anderson CM, Killick R, Yu X, Jefferys JG, Duff K Functional Phenotype in Transgenic Mice Expressing Mutant Human Presenilin-1. Neurobiol Dis 2000 7, 119-126. Abstract.

Associated:

4. Holcomb L, Gordon M, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O?Campo K, Hardy J, Prada C, Eckman C, Younkin S, Hsiao K, Duff K. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature. Med, Vol. 4 (No 1); p.97. Abstract.

5. T-P Wong, T. Debeir, K. Duff, and A.C Cuello. (1999) Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1, and amyloid precursor protein transgenes J. Neuroscience, 19 (7) 2706-2716. Abstract.

6. McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, Yu X, Uljon, S.E., Wang R, Mann D, Dickson D, Duff K. (1999) Amyloid phenotype characterization of transgenic mice over-expressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis 6, 231-244. Abstract.

7. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D (1999). Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet; 29: 177-85. Abstract.

8. A. Takeuchi, E. M. Irizarry, K. Duff, T. Saido, K. Hsiao Ashe, D. Mann , B Hyman and T. Iwatsubo. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal los  (Am J Pathol 2000, vol 157 p.331-339). Abstract.

9. L. Refolo, M. Pappolla, B. Malester, J. LaFrancois, R. Wang, G. Tint, K. Sambamurti, T. Bryant-Thomas and K. Duff. Hypercholesterolemia accelerates amyloid pathology in a transgenic mouse model for Alzheimer?s disease amyloidosis. Neurobiol Dis. 2000 Aug;7(4):321-31. Abstract.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark

See recent updates
Alzheimer's Disease Mouse Model Resource
Considerations for Choosing Controls
Research Tools

Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad